Advanced Tumors clinical trials

ZW251 for advanced solid tumors

This trial is testing a new drug called ZW251 for people with advanced liver cancer (hepatocellular carcinoma), non-small cell lung cancer, or germ cell tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.

Fulzerasib Plus Cetuximab for Advanced Colorectal Cancer With KRAS G12C

This trial tests a combination of two drugs (fulzerasib and cetuximab) given before surgery to shrink locally advanced colorectal cancer that has a specific genetic mutation called KRAS G12C. The goal is to help make the cancer easier to remove surgically and improve outcomes.

Study of REGN10597 with or without cemiplimab for advanced solid tumors

This study tests a new drug called REGN10597, either alone or with cemiplimab, for people with advanced solid tumors (like melanoma or kidney cancer) that have not responded to standard treatments. The goal is to see if the combination can shrink tumors or slow their growth.

ADCX-020 for advanced or metastatic cancers

This trial tests a new drug, ADCX-020, for people with advanced solid tumors that have stopped responding to standard treatments. The drug targets cancer cells directly and may offer a new option when other treatments have failed.

CUE-101 plus pembrolizumab for HPV+ throat cancer

This trial tests a new drug called CUE-101 combined with a standard immunotherapy (pembrolizumab) for people with HPV-16 positive head and neck cancer that cannot be removed with surgery. The goal is to see if this combination can shrink or control the cancer.

RET-targeting drug study for advanced cancers with RET changes

This trial tests an “RET-inhibitor” medicine (TAS0953/HM06) for advanced solid tumors that have RET gene changes. It may help shrink tumors by blocking cancer growth signals from the RET gene.

Personalized mRNA vaccine for advanced endocrine tumors

This trial tests a personalized mRNA vaccine made from your tumor's genetic information. It is for people with advanced endocrine tumors who have no standard treatment options left, and aims to help the immune system fight the cancer.

IDOV-Immune vaccine for advanced solid tumors

This trial tests an experimental virus-based treatment for people with advanced solid tumors that have stopped responding to standard therapies. The treatment is designed to infect and destroy cancer cells while boosting the immune system.

A new oral drug for KRAS-mutated advanced cancer

This trial tests a new oral drug, KST-6051, for people with advanced solid tumors (like lung, pancreatic, colon, or other cancers) that have a specific KRAS gene mutation. The goal is to find the best dose and see if it's safe.

Study of MT-4561 for advanced solid tumors

This trial tests a new drug called MT-4561 in people with advanced solid tumors that have not responded to prior treatments. It aims to see if the drug can help shrink tumors or slow their growth.

Study of injected ONM-501 alone or with cemiplimab for advanced cancers

This trial tests an injected study drug (ONM-501) alone or with another drug (cemiplimab) for people with advanced solid tumors or lymphomas that haven't responded to other treatments. It aims to find a safe dose and see if the combination helps shrink or control the cancer.

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.

Testing BMS-986507 for advanced lung and breast cancers

This study tests a new drug called BMS-986507, given in different combinations, for people with advanced solid tumors (lung cancer or breast cancer that has spread). It looks at safety, how the drug works in the body, and if it helps shrink tumors.

New Cancer Drug Treatment for Advanced Lung, Esophageal, or Skin Cancer

This study tests a new drug called PF-08046033 in people with advanced lung cancer (NSCLC), esophageal cancer (ESCC), or melanoma (skin cancer) that has spread or can't be surgically removed. The drug targets a specific protein to help slow or stop cancer growth.

Testing Calderasib for advanced solid tumors with KRAS G12C mutation

This trial tests a new drug, Calderasib (MK-1084), for people with advanced solid tumors that have a specific KRAS G12C mutation and aren't getting better with standard treatments. The goal is to see if the drug can help shrink or control the cancer.

Study of GTAEXS617 for advanced solid tumors

This trial tests a new drug called GTAEXS617 for adults with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.

JAB-21822 plus JAB-3312 for KRAS G12C solid tumors

This Phase 1/2a trial tests two investigational pills (JAB-21822 and JAB-3312) in people with advanced solid cancers that have a KRAS G12C mutation. It’s for cases where standard treatments have failed or aren’t suitable, to see if the drugs can shrink tumors and improve outcomes.

Testing new cancer immunotherapy for advanced ovarian cancer

This study tests two new experimental drugs (XmAb541 and XmAb808) designed to fight advanced ovarian cancer by activating your immune system. You'll be closely monitored to see how safe the drugs are and how your body tolerates them.

Safety Study of KUP-101A in Advanced Solid Tumors

This is an early-stage study testing a new drug called KUP-101A in patients with advanced solid cancers (like lung, colon, or breast cancer) that haven't responded to standard treatments. The drug works by activating the immune system to fight cancer.

Combining two immunotherapies for solid tumors, melanoma, and lung cancer

This trial tests a new drug (bexmarilimab) plus nivolumab (an approved immunotherapy) for people with advanced solid tumors, melanoma, or non-small cell lung cancer (NSCLC) that has stopped responding to standard treatments.

Testing a new drug for advanced solid tumors

This trial is testing a new drug (BMS-986517) for people with advanced solid tumors, including certain lung, head and neck, and breast cancers. The goal is to see if the drug is safe and effective.

DM005 for Advanced Solid Tumors

This study tests a new drug called DM005 for people with advanced solid tumors (like lung, stomach, colon, liver, pancreas, or head and neck cancer) that have not responded to or can't tolerate standard treatments. The goal is to see if DM005 is safe and how well it works.

Study of DM002 for advanced solid tumors

This trial tests a new drug called DM002 for people with advanced solid tumors that have not responded to standard treatments. The drug targets two proteins (MUC1 and HER3) found on some cancer cells, and may help shrink tumors or slow their growth.